Suven Life Sciences secures three product patents in Canada and China

16 Sep 2015 Evaluate

Suven Life Sciences has secured two product patents from Canada and one product patent from China corresponding to its New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029 and 2030.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

With these new patents, Suven has a total of twenty granted patents from Canada and eighteen granted patents from China. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.


Suven Life Sciences Share Price

129.30 1.90 (1.49%)
28-Jan-2026 11:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1617.05
Dr. Reddys Lab 1221.75
Cipla 1318.35
Zydus Lifesciences 890.85
Lupin 2122.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×